Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 8,174 shares at $12.80 ($105K) on 2025-10-30, disclosed to the SEC on 2025-10-30.
Open-market sale of $105k NRIX by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.80 | 4,087 | $52K | 50.0% |
| 2 | $12.80 | 4,087 | $52K | 50.0% |
| Total | $12.80 avg | 8,174 | $105K | 100% |
| Filing → |
| NRIX | SELL | 2026-08-05 | $109K | — | Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |